VeriChip Corporation (NASDAQ:CHIP), a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs, announced today more than 90 Alzheimer's patients and caregivers received the VeriMed? RFID implantable microchip last week at the official launch of the VeriMed Patient Identification Project with Alzheimer's Community Care. VeriChip's collaboration with Alzheimer's Community Care consists of a voluntary, two-year, 200 patient project to evaluate the effectiveness of the VeriMed? Patient Identification System in managing the records of Alzheimer's patients and their caregivers

?We couldn't be more pleased with the results of last week's project launch with Alzheimer's Community Care,? said Scott R. Silverman, Chairman and CEO of VeriChip Corporation. ?We had an excellent turn-out at the educational seminars and virtually 100% enrollment. This overwhelming acceptance underscores the value of the VeriMed system not only for Alzheimer's patients, but their caregivers as well. We are optimistic that we will complete our patient enrollment for this important study ahead of schedule and demand within targeted high-risk patient categories will continue to grow.?

About Alzheimer's Community Care

The mission of Alzheimer's Community Care is to promote and provide specialized, compassionate, quality care to Alzheimer's disease and related disorders patients and their caregivers and ensure their safety, health and well being while preserving their dignity within a community-based environment. The organization serves as an innovative model of care which advocates for services and resources which are dementia-specific, accessible, affordable, individualized, and evidence-based. Alzheimer's Community Care has been serving the community since 1996.

About VeriChip Corporation

VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.

VeriChip Corporation is majority-owned by Applied Digital Inc. (Nasdaq:ADSX), which also owns a majority position in Digital Angel Corporation (AMEX:DOC). For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com.

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

VeriChip Corporation, Delray Beach
Allison Tomek, 561-805-8008
atomek@adsx.com
or
CEOcast
Dan Schustack, 212-732-4300